Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic?

Maja Baretić

A type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chloroquine should be monitored for hypoglycaemia, even after recovery.

© 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Dear Editor,

I read with great interest article by Singh AK et al. [1] and would like to share a case of a patient with type 1 diabetes mellitus (T1DM) and the possible long-term consequences of chloroquine therapy.

A 26-year old man was diagnosed with T1DM in 2007. His body mass index was 27 kg/m², C peptide 0.19 nmol/L, A1C 7.5% and he had striking hyperglycaemia with positive pancreatic antibodies confirming autoimmunity, so he was treated with insulin. Shortly thereafter, he started to use prophylactic chloroquine phosphate (500 mg once a week for 4 consecutive weeks) due to a trip to a malaria-endemic area and experienced hypoglycaemia following 2 weeks of therapy. Insulin was gradually reduced and eventually stopped. In the next years, he was able to keep his blood glucose optimal with dietary measures alone with A1C 6.2–6.9% (44–52 mg/mol), HOMA index 1.7; fasting C peptide was 0.74 nmol/L, after a meal C peptide was 0.61 nmol/L confirming residual endogenous secretion of insulin, but A1C 9.2% (77 mmol/L).

Is remission of T1DM associated with chloroquine, a drug also used for the treatment of autoimmune disorders (rheumatoid arthritis) and known to cause hypoglycaemia? With the natural progression of T1DM, some patients regain transient β-cell activity which lasts in most cases a few weeks or months, or rarely, years. The factors that prolong partial recovery from an autoimmune attack are still unknown. Chloroquine, however, is known to reduce the incidence of diabetes in patients with rheumatoid arthritis and lupus and to improve glycaemia if diabetes is already present [2]. The anti-inflammatory mechanisms of chloroquine are possibly related to lysosomotropic and immunomodulatory mechanisms [3], but chloroquine also causes changes in insulin metabolism through the signalling of cellular receptors and post-receptor clearance [4]. In diabetic animals, it has been shown that chloroquine raises serum insulin levels even without exogenous insulin treatment [5].

Patients with T1DM are likely to have worse outcomes with COVID-19 infection. If infected, there may be a chance that they will be treated with chloroquine which has been associated with positive outcomes in COVID-19-related pneumonia. If so, and there is still some β-cell activity present, it might precipitate hypoglycaemia which is associated with increased mortality in subjects hospitalised with pneumonia, regardless of whether they have
diabetes [6].
What is the lesson from this case? Chloroquine has both immunomodulatory and hypoglycaemic effects. In the future, we might use chloroquine more frequently due to the COVID-19 pandemic, including in patients with T1DM. Such patients should be monitored closely for hypoglycaemia and if necessary, their insulin dose must be adjusted, even after recovery.

Declaration of competing interest
Author of the paper has no competing interests and did not receive any financial resource for publication and authorship. Patient has signed informed consent for the publication of particular material.

References
[1] Singh AK, Singh A, Shaikh A, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes, Metab Syndrome Clin Res Rev 2020;14:241–6.
[2] Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. J Am Med Assoc 2007;298:87–93.
[3] Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford) 2015;54:1244–9.
[4] Hage MP, Al-Ibadri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab 2014;5:77–85.
[5] Mahmoud AB, Alghriany AA, Shakor AB. The effect of chloroquine induced hypoglycaemia on the levels of major blood serum proteins in diabetic mice. Egypt Acad J Biol Sci C Physiol Mol Biol 2014;6:138–48.
[6] Mortensen EM, Garcia S, Leykum L, et al. Association of hypoglycemia with mortality for subjects hospitalized with pneumonia. Am J Med Sci 2010;339:239–43.